Etanercept News and Research

RSS

Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

Study may one day lead to a new treatment for preventing cerebral palsy

Severe brain injury that develops slowly after preterm births, causing the likes of cerebral palsy, may be treatable, new research from the University of Auckland finds.

29 Sep 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented today at EADV’s 30th Congress.

1 Oct 2021

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Uveitis is an inflammation of the eye and is a common extra-articular manifestation associated with juvenile idiopathic arthritis (JIA). It can cause vision-threatening complications, and if left uncontrolled may even lead to blindness.

18 Jun 2021

Immune-inflammatory mediators indicate that rejection and tissue injury can be avoided with drugs

Immune inflammatory mediators are critical in pathology, transplantation, and regenerative medicine, scientists report in The American Journal of Pathology

22 Dec 2020

Secukinumab for treatment of plaque psoriasis in children: Added benefit not proven

The monoclonal antibody secukinumab is approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of six years who are candidates for systemic therapy.

5 Dec 2020

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity are more often affected by thrombosis.

5 Jun 2020

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.

11 Nov 2019

Optimal therapy for Down syndrome arthropathy remains unclear, reveals study

A new study found that patients with Down syndrome arthropathy continue to have an approximate year-long delay in diagnosis from the onset of their symptoms, and that optimal therapy for this condition remains unclear.

11 Nov 2019

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

10 Nov 2019

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.

10 Nov 2019

New therapeutic target for rheumatoid arthritis and type 2 diabetes

There is a growing body of knowledge that points that type 2 diabetes, a chronic disease where the blood sugar increases, is an inflammatory disease. The levels of certain inflammatory chemicals, dubbed as cytokines, are often higher in people with type 2 diabetes, than healthy people.

16 Sep 2019

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Celecoxib combined with TNF inhibitors was associated with the greatest reduction in radiographic progression.

14 Jun 2018

Old World monkeys could hold key to stop progression of rheumatoid arthritis

In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa.

17 Nov 2017

FOI technique found to be effective in detecting joint inflammation in children

The results of a study presented today at the Annual European Congress of Rheumatology 2017 have confirmed that Fluorescence Optical Imaging, a technique used to visualize inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis.

14 Jun 2017

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug-target binding in a physiological environment and at clinically-relevant concentrations.

15 May 2017

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016